New combination therapies targeting lipid and glutamine metabolism for glioblastoma
Official title: Novel lipid and glutamine metabolism-based combination therapies for glioblastoma
Funded at Ohio State University · NIH-11070872 · Data updated 2026-11-12
This study is looking at new ways to treat glioblastoma, a tough brain tumor, by testing a drug called pimozide that might help stop the tumor from growing by cutting off its food supply, and so far, it’s showing good results in animals without causing major side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | January 15, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $629,750 |
| NIH project number | 1R01NS141312-01 |
| Project ID | NIH-11070872 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking new treatment options.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
What this research studies
This research investigates innovative therapies for glioblastoma, a highly aggressive brain tumor. It focuses on how glioblastoma cells utilize lipids and glutamine for growth and explores the potential of a drug called pimozide, which inhibits lysosomal function, to disrupt this process. By blocking the supply of essential lipids and glutamine, the research aims to effectively reduce tumor growth. Initial tests in animal models have shown promising results without significant side effects.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with glioblastoma, potentially improving survival rates.
How similar studies have gone: Other research has shown success in targeting metabolic pathways in cancer treatment, suggesting that this approach may also be effective for glioblastoma.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Guo, Deliang — Ohio State University
- Study coordinator: Guo, Deliang
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.